Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Chiang, Cheryl L L ^a   Maier, Dawn A ^b   Kandalaft, Lana E ^a   Brennan, Andrea L ^b   Lanitis, Evripidis ^a   Ye, Qunrui ^a   Levine, Bruce L ^b   Czerniecki, Brian J ^b   Powell, Daniel J ^a   Coukos, George ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; DIMETHYL SULFOXIDE; GAMMA INTERFERON; GLUCOSE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN SERUM ALBUMIN; HYPOCHLOROUS ACID; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT ENZYME; SODIUM CHLORIDE; TRYPSIN; CELL EXTRACT;

ARTICLE; BLOOD GROUP AB; CELL ACTIVATION; CELL LYSATE; CELL MATURATION; CELL VIABILITY; CONTROLLED STUDY; CRYOPRESERVATION; CULTURE MEDIUM; CULTURE OPTIMIZATION; DENDRITIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MIXED LYMPHOCYTE REACTION; PHENOTYPE; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; PROTEIN SECRETION; TUMOR CELL; BIOSYNTHESIS; CELL DIFFERENTIATION; CELL SURVIVAL; CULTURE TECHNIQUE; CYTOLOGY; DRUG EFFECT; METABOLISM; METHODOLOGY; MIXED LYMPHOCYTE CULTURE; OXIDATION REDUCTION REACTION; SECRETION; TIME; TUMOR CELL LINE;

CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL EXTRACTS; CELL LINE, TUMOR; CELL SURVIVAL; CRYOPRESERVATION; CULTURE MEDIA; DENDRITIC CELLS; HUMANS; HYPOCHLOROUS ACID; INTERLEUKIN-12; LYMPHOCYTE CULTURE TEST, MIXED; OXIDATION-REDUCTION; PHENOTYPE; TIME FACTORS; TRYPSIN;

EID: 81055127506     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-198     Document Type: Article

References (48)

1. Thurner B, Röder C, Dieckmann D, Heuer M, Kruse M, Glaser A, Keikavoussi P, Kämpgen E, Bender A, Schuler G. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999, 223:1-15. 10.1016/S0022-1759(98)00208-7, 10037230.
2. Berger TG, Strasser E, Smith R, Carste C, Schuler-Thurner B, Kaempgen E, Schuler G. Efficient elutriation of monocytes within a closed system (Elutra™) for clinical-scale generation of dendritic cells. J Immunol Methods 2005, 298:61-72. 10.1016/j.jim.2005.01.005, 15847797.
3. Berger TG, Feuerstein B, Strasser E, Hirsch U, Schreiner D, Schuler G, Schuler-Thurner B. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories™. J Immunol Methods 2002, 268:131-140. 10.1016/S0022-1759(02)00189-8, 12215381.
4. Kim S, Kim HO, Baek EJ, Choi Y, Kim HS, Lee MG. Monocyte enrichment from leukapheresis products by using the Elutra cell separator. Transfusion 2007, 47:2290-2296. 10.1111/j.1537-2995.2007.01470.x, 17764512.
5. Pickl W, Majdic O, Kohl P, Stockl J, Riedl E, Scheinecker C, Bello-Fernandez C, Knapp W. Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes. J Immunol 1996, 157:3850-3859.
6. Wong E, Lee S, Hines K, Lee J, Carter C, Kopp W, Bender J, Read E. Development of a closed-system process for clinical-scale generation of DCs: evaluation of two monocyte-enrichment methods and two culture containers. Cytotherapy 2002, 4:65-76. 10.1080/146532402317251545, 11953043.
7. Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 1996, 196:121-135. 10.1016/0022-1759(96)00079-8, 8841451.
8. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells. Nat Med 1998, 4:328-332. 10.1038/nm0398-328, 9500607.
9. Hernando JJPT, Kübler K, Offergeld R, Schlebusch H, Bauknecht T. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 2002, 51:45-52. 10.1007/s00262-001-0255-1, 11845259.
10. Nagayama H, Sato K, Morishita M, Uchimaru K, Oyaizu N, Inazawa T, Yamasaki T, Enomoto M, Nakaoka T, Nakamura T, et al. Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res 2003, 13:521-530. 10.1097/00008390-200310000-00011, 14512794.
11. Märten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, Caspari R, Flieger D, Hanfland P, von Ruecker A, et al. Allogeneic Dendritic Cells Fused with Tumor Cells: Preclinical Results and Outcome of a Clinical Phase I/II Trial in Patients with Metastatic Renal Cell Carcinoma. Hum Gene Ther 2003, 14:483-494. 10.1089/104303403321467243, 12691613.
12. Maier T, Tun-Kyi A, Tassis A, Jungius K-P, Burg G, Dummer R, Nestle FO. Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 2003, 102:2338-2344. 10.1182/blood-2002-08-2455, 12714511.
13. Gitlitz BJ, Belldegrun AS, Zisman A, Chao DH, Pantuck AJ, Hinkel A, Mulders P, Moldawer N, Tso C-L, Figlin RA. A Pilot Trial of Tumor Lysate-Loaded Dendritic Cells for the Treatment of Metastatic Renal Cell Carcinoma. J Immunother 2003, 26:412-419. 10.1097/00002371-200309000-00004, 12973030.
14. Iwashita Y, Tahara K, Goto S, Sasaki A, Kai S, Seike M, Chen C-L, Kawano K, Kitano S. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother 2003, 52:155-161.
15. Pandha HS, John RJ, Hutchinson J, James N, Whelan M, Corbishley C, Dalgleish AG. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int 2004, 94:412-418. 10.1111/j.1464-410X.2004.04922.x, 15291878.
16. Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H, Pasha T, Xu M, Fox KR, et al. Targeting HER-2/neu in Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion. Cancer Res 2007, 67:1842-1852. 10.1158/0008-5472.CAN-06-4038, 17293384.
17. Dauer M, Lam V, Arnold H, Junkmann J, Kiefl R, Bauer C, Schnurr M, Endres S, Eigler A. Combined use of toll-like receptor agonists and prostaglandin E2 in the FastDC model: Rapid generation of human monocyte-derived dendritic cells capable of migration and IL-12p70 production. J Immunol Methods 2008, 337:97-105. 10.1016/j.jim.2008.07.003, 18657542.
18. Dauer M, Obermaier B, Herten J, Haerle C, Pohl K, Rothenfusser S, Schnurr M, Endres S, Eigler A. Mature Dendritic Cells Derived from Human Monocytes Within 48 Hours: A Novel Strategy for Dendritic Cell Differentiation from Blood Precursors. J Immunol 2003, 170:4069-4076.
19. Chiang CL-L, Benencia F, Coukos G. Whole tumor antigen vaccines. Semin Immunol 2010, 22:132-143. 10.1016/j.smim.2010.02.004, 3119500, 20356763.
20. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003, 421:852-856. 10.1038/nature01441, 12594515.
21. Shedlock DJ, Shen H. Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory. Science 2003, 300:337-339. 10.1126/science.1082305, 12690201.
22. Sun JC, Williams MA, Bevan MJ. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 2004, 5:927-933. 10.1038/ni1105, 2776074, 15300249.
23. Chiang CL, Ledermann J, Rad AN, Katz D, Chain B. Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-specific T cells. Cancer Immunol Immunother 2006, 55:1384-1395. 10.1007/s00262-006-0127-9, 16463039.
24. Chiang CL, Ledermann JA, Aitkens E, Benjamin E, Katz DR, Chain BM. Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor. Clin Cancer Res 2008, 14:4898-4907. 10.1158/1078-0432.CCR-07-4899, 18676764.
25. Prokopowicz ZM, Arce F, Biedron R, Chiang CL-L, Ciszek M, Katz DR, Nowakowska M, Zapotoczny S, Marcinkiewicz J, Chain BM. Hypochlorous Acid: A Natural Adjuvant That Facilitates Antigen Processing, Cross-Priming, and the Induction of Adaptive Immunity. J Immunol 2010, 184:824-835. 10.4049/jimmunol.0902606, 20018624.
26. Fisk B, Belvins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995, 181:2109-17. 10.1084/jem.181.6.2109, 2192068, 7539040.
27. Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins P, Marincola F, Salgaller M, Yannelli J, Appella E. Induction of tumor-reactive CTL from peripheral blood and tumor- infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995, 154:2257-2265.
28. Romero P, Gervois N, Schneider J, Escobar P, Valmori D, Pannetier C, Steinle A, Wolfel T, Lienard D, Brichard V, et al. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201- restricted Melan-A/MART-1 antigenic peptide in melanoma. J Immunol 1997, 159:2366-2374.
29. Garderet L, Cao H, Salamero J, Vergé V, Tisserand E, Scholl S, Gorin N-C, Lopez M. In Vitro Production of Dendritic Cells from Human Blood Monocytes for Therapeutic Use. J Hematother Stem Cell Res 2001, 10:553-567. 10.1089/15258160152509163, 11522238.
30. Erdmann M, Schuler-Thurner B. Towards a Standardized Protocol for the Generation of Monocyte-Derived Dendritic Cell Vaccines. Methods Mol Biol 2010, 595:149-63. 10.1007/978-1-60761-421-0_9, 19941110.
31. Morse M, Clay T, Colling K, Lyerly H. Preparation of peptide-loaded dendritic cells for cancer immunotherapy. Mol Biotechnol 2003, 25:95-99. 10.1385/MB:25:1:95, 13679640.
32. Loudovaris M, Hansen M, Suen Y, Lee SM, Casing P, Bender JG. Differential Effects of Autologous Serum on CD34+ or Monocyte-Derived Dendritic Cells. J Hematothera Stem Cell Res 2001, 10:569-578.
33. Selvaggi TA, Walker RE, Fleisher TA. Development of Antibodies to Fetal Calf Serum With Arthus-Like Reactions in Human Immunodeficiency Virus-Infected Patients Given Syngeneic Lymphocyte Infusions. Blood 1997, 89:776-779.
34. Mackensen A, Drager R, Schlesier M, Mertelsmann R, Lindemann A. Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol Immunother 2000, 49:152-156. 10.1007/s002620050614, 10881694.
35. Tuschong L, Soenen SL, Blaese RM, Candotti F, Muul LM. Immune Response to Fetal Calf Serum by Two Adenosine Deaminase-Deficient Patients After T Cell Gene Therapy. Hum Gene Ther 2002, 13:1605-1610. 10.1089/10430340260201699, 12228015.
36. Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, Fogli M, Ferri E, Della Cuna GR, Tura S, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002, 100:230-237. 10.1182/blood.V100.1.230, 12070032.
37. Beckebaum S, Zhang X, Chen X, Yu Z, Frilling A, Dworacki G, Grosse-Wilde H, Erich Broelsch C, Gerken G, Cicinnati VR. Increased Levels of Interleukin-10 in Serum from Patients with Hepatocellular Carcinoma Correlate with Profound Numerical Deficiencies and Immature Phenotype of Circulating Dendritic Cell Subsets. Clin Cancer Res 2004, 10:7260-7269. 10.1158/1078-0432.CCR-04-0872, 15534100.
38. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, et al. Induction of CD8+ T-Cell Responses Against Novel Glioma-Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma. J Clin Oncol 2011, 29:330-336. 10.1200/JCO.2010.30.7744, 21149657.
39. DeBenedette MA, Calderhead DM, Tcherepanova IY, Nicolette CA, Healey DG. Potency of Mature CD40L RNA Electroporated Dendritic Cells Correlates With IL-12 Secretion by Tracking Multifunctional CD8+/CD28+ Cytotoxic T-cell Responses In Vitro. J Immunother 2011, 34:45-57. 10.1097/CJI.0b013e3181fb651a, 21150712.
40. Watchmaker PB, Berk E, Muthuswamy R, Mailliard RB, Urban JA, Kirkwood JM, Kalinski P. Independent Regulation of Chemokine Responsiveness and Cytolytic Function versus CD8+ T Cell Expansion by Dendritic Cells. J Immunol 2010, 184:591-597. 10.4049/jimmunol.0902062, 2922038, 20018619.
41. Butterfield LH, Gooding W, Whiteside TL. Development of a Potency Assay for Human Dendritic Cells: IL-12p70 Production. J Immunother 2008, 31:89-100. 10.1097/CJI.0b013e318158fce0, 18157016.
42. Lopez MN, Pereda C, Segal G, Munoz L, Aguilera R, Gonzalez FE, Escobar A, Ginesta A, Reyes D, Gonzalez R, et al. Prolonged Survival of Dendritic Cell-Vaccinated Melanoma Patients Correlates With Tumor-Specific Delayed Type IV Hypersensitivity Response and Reduction of Tumor Growth Factor (beta)-Expressing T Cells. J Clin Oncol 2009, 27:945-952. 10.1200/JCO.2008.18.0794, 19139436.
43. Lau R, Wang F, Jeffery G, Marty V, Kuniyoshi J, Bade E, Ryback ME, Weber J. Phase I Trial Of Intravenous Peptide-Pulsed Dendritic Cells in Patients With Metastatic Melanoma. J Immunother 2001, 24:66-78. 10.1097/00002371-200101000-00008, 11211150.
44. Escobar A, López M, Serrano A, Ramirez M, Pérez C, Aguirre A, González R, Alfaro J, Larrondo M, Fodor M, et al. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol 2005, 142:555-568. 1809550, 16297169.
45. von Euw E, Barrio M, Furman D, Levy E, Bianchini M, Peguillet I, Lantz O, Vellice A, Kohan A, Chacon M, et al. A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression. J Transl Med 2008, 6:6-19. 10.1186/1479-5876-6-6, 2265680, 18221542.
46. Ridolfi R, Petrini M, Fiammenghi L, Stefanelli M, Ridolfi L, Ballardini M, Migliori G, Riccobon A. Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients. J Transl Med 2006, 4:36-46. 10.1186/1479-5876-4-36, 1562447, 16914047.
47. Rouas R, Akl H, Fayyad-Kazan H, El Zein N, Badran B, Nowak B, Duvillier H, Martiat P, Lewalle P. Dendritic Cells Generated in Clinical Grade Bags Strongly Differ in Immune Functionality When Compared With Classical DCs Generated in Plates. J Immunother 2010, 33:352-363. 10.1097/CJI.0b013e3181cc266b, 20386471.
48. Rapoport AP, Stadtmauer EA, Aqui N, Vogl D, Chew A, Fang H-B, Janofsky S, Yager K, Veloso E, Zheng Z, et al. Rapid Immune Recovery and Graft-versus-Host Disease-like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells. Clin Cancer Res 2009, 15:4499-4507. 10.1158/1078-0432.CCR-09-0418, 2828291, 19509133.